Breast Cancer
Conditions
Keywords
Breast cancer, screening, survival
Brief summary
This is a multicenter retrospective cohort of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)). The objective is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives. This study is part of a broader project (CAMISS study), which also includes one prospective cohort (CAMISS Prospective cohort - Identifier in ClinicalTrials.gov: NCT02439554).
Detailed description
The general objective for this study is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives. The cohort has information of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a breast cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)). Expected results: Nowadays there are no results of cohort analysis of the diagnostic process of care that integrates all those different aspects. This study will complement the evaluation of population screening, specifically the interval cancer and the impact on survival and disease-free period taking into account relevant variables like breast density, tumor phenotype, clinical complications, readmissions, and the surgical approach. This study is part of a broader project (CAMISS study) coordinated by the Evaluation of Health Services of Epidemiology and Public Health Group, which consists of two cohorts of women diagnosed with breast cancer: a prospective cohort (n=2,040 incident cases of breast cancer diagnosed in 18 hospitals of 5 Spanish regions) (Identifier in ClinicalTrials.gov: NCT02439554) and a retrospective cohort of screened women diagnosed with breast cancer between 2000 and 2009 in two Spanish regions (n=1,086). The general objective of the CAMISS study is to evaluate different aspects of health care received by patients with breast cancer like the diagnostic process, treatment, complications, survival, costs and quality of life to provide information to improve the effectiveness and cost-effectiveness of interventions, reduce variability, have better predictive rules and increase the quality of life.
Interventions
PROCEDUREMode of detection: Cancer detected at screening
Cancers detected as a result of screening mammograms.
PROCEDUREMode of detection: Interval cancer
Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
Sponsors
Fondo de Investigacion Sanitaria
European Regional Development Fund
Red de Investigación en Servicios de Salud en Enfermedades Crónicas
Parc de Salut Mar
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* Women aged between 50 to 69 years with invasive or in situ breast cancer.
Exclusion criteria
* Women diagnosed with lobular carcinoma in situ.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | From date of cancer diagnosis until the date of death from any cause, assessed up to 14 years | Death from any cause |
Secondary
| Measure | Time frame |
|---|---|
| Recurrences and second breast neoplasms | From date of cancer diagnosis until the date of the first recurrence or second breast neoplasm, whichever came first, assessed up to 14 years |
| Treatment-related complications | From the date of surgery until the end of follow-up, assessed up to 14 years. |
| Readmissions to hospital for reasons related to breast cancer | From the date of surgery until the end of follow-up, assessed up to 14 years. |
Outcome results
None listed